Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study
ConclusionOur findings contribute to the selection and clinical management of NIVO-IPI and NIVO-CABO, which minimizes the risk of AEs for individual patients with mRCC by considering distinctive differences in the AE profiles.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Gastroenterology | Hepatitis | International Medicine & Public Health | Kidney Cancer | Myocarditis | Renal Cell Carcinoma | Skin | Study | WHO | Yervoy